Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amylyx PharmaceuticalsAMLX +4.72%33 Debt-to-Equity is 0.02 as of Mar. 2026, which is 100% above its 10-year median of 0.01. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 811 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 93.09% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Amylyx Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
AMLX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.59 Med: 0.01 Max: 0.05
Current: 0.02
During the past 7 years, the highest Debt-to-Equity Ratio of Amylyx Pharmaceuticals was 0.05. The lowest was -0.59. And the median was 0.01.
AMLX's Debt-to-Equity is ranked better than 93.09% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs AMLX: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Amylyx Pharmaceuticals Debt-to-Equity Related Terms
Amylyx Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Amylyx Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMLX vs ANIP, TRLV, PBH: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (AMLX) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Amylyx Pharmaceuticals and its competitors. This is 100% above median its historical median of 0.01. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #56 out of 811 companies in the Drug Manufacturers industry, placing it in the top 6.9%.
Is Amylyx Pharmaceuticals' Debt-to-Equity too high?
Amylyx Pharmaceuticals' current Debt-to-Equity of 0.02 is 100% above median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Amylyx Pharmaceuticals' value of 0.02 is 92.6% below this industry median. Based on the distribution chart, Amylyx Pharmaceuticals ranks #56 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Debt-to-Equity compare to ANIP and TRLV?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #56 out of 811 companies for Debt-to-Equity. This places Amylyx Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Amylyx Pharmaceuticals' value of 0.02 is 92.6% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.27, Amylyx Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amylyx Pharmaceuticals's current Debt-to-Equity of 0.02 is 92.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current Debt-to-Equity is 0.02, which is 100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02, which is 100% above median its 10-year median of 0.01 and 92.6% below the Drug Manufacturers industry median of 0.27. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
